Online citations, reference lists, and bibliographies.

Re: Marko Babjuk, Andreas Böhle, Maximilian Burger, Et Al. EAU Guidelines On Non-muscle-invasive Urothelial Carcinoma Of The Bladder: Update 2016. Eur Urol 2017;71:447-61.

H. Herr
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The 2016 European Association of Urology guidelines on nonmuscle-invasive bladder cancer is exemplary; however, the definition of Bacillus Calmette–Guérin (BCG)-refractory remains confusing [1]. One BCG-refractory category (Table 9 in the European Association of Urology guidelines) lists ‘‘high-grade papillary tumor present at 3 mo, because further conservative treatment with BCG is associated with increased risk of progression.’’ Although common to determine BCG response after 3 mo [2], is this is too soon (only 6 wk after last dose of 6-weekly induction regimen) to
This paper references



This paper is referenced by
10.1038/s41598-018-27538-3
Bladder cancer recurrence surveillance by urine metabolomics analysis
A. Loras (2018)
10.1007/s00428-020-02755-2
PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders
Francesco Pierconti (2020)
10.1016/j.urolonc.2016.11.014
Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy.
K. Matsumoto (2017)
10.1007/978-3-319-74942-6_7
Molecular Cytology Applications on Urine
S. Savic (2018)
10.1007/978-981-32-9147-8_2
Types of Cancer
Bansi Lal Koul (2019)
10.1186/s13148-018-0496-x
Urine cell-based DNA methylation classifier for monitoring bladder cancer
A. G. van der Heijden (2018)
10.1007/s00330-020-06796-8
Elaboration of a multisequence MRI-based radiomics signature for the preoperative prediction of the muscle-invasive status of bladder cancer: a double-center study
Huanjun Wang (2020)
10.1007/s00330-019-06119-6
Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression
Shugo Yajima (2019)
10.1159/000489502
Psychosocial Distress in Bladder Cancer Stratified by Gender, Age, Treatment, and Tumour Stage
D. Draeger (2018)
10.1007/s00761-017-0325-4
Epidemiologie des Harnblasenkarzinoms in Deutschland
K. Kraywinkel (2017)
10.1016/j.urology.2016.07.009
Nonmuscular Invasive Urothelial Carcinoma of the Bladder in Pediatric and Young Adult Patients: Age-related Outcomes.
Paolo Caione (2017)
10.1007/s00345-019-02915-3
Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator
Miles P Mannas (2019)
10.1007/s00345-020-03143-w
Preliminary study on the application of en bloc resection combined with near-infrared molecular imaging technique in the diagnosis and treatment of bladder cancer
Yongjun Yang (2020)
10.1007/s00345-018-2581-3
Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system
H. Kim (2018)
10.1007/s00092-017-1708-y
Die En-bloc-Resektion des Harnblasentumors
J. Struck (2017)
10.1007/s00345-017-2147-9
Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study
Maximilian C. Kriegmair (2017)
10.1016/j.euf.2016.12.004
Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer.
M. Kramer (2017)
10.1007/s00432-018-2593-9
Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer
F. Sanguedolce (2018)
10.1007/s11934-020-0966-5
Blue Light Cystoscopy: Indications and Outcomes
Kamal S. Pohar (2020)
10.1016/j.eururo.2017.05.054
Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
J. Bosschieter (2018)
10.1007/978-3-319-64769-2_8
Urine Cytology and Existing Urinary Biomarkers for Bladder Cancer
T. Longo (2018)
10.1016/j.eururo.2016.11.004
Reply from Authors re: Peter Albers. Surveillance of Patients with Clinical Stage I Testis Cancer is Safe and Will Remain Unchanged. Eur Urol 2017;71:130-131.
Madhur Nayan (2017)
10.1016/j.eururo.2016.12.016
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
E. Christensen (2017)
10.1016/j.euf.2016.10.004
A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.
N. Davis (2018)
10.1016/j.urology.2017.05.032
When the Gold Standard Proves to Be Fool's Gold-Blue-light Cystoscopy in a Case of High-risk Non-muscle-invasive Bladder Cancer.
Kaitlyn M. Dunphy (2017)
10.1007/S40267-017-0436-4
Hexaminolevulinate: a profile of its use with blue-light cystoscopy in the diagnosis of bladder cancer
Katherine A. Lyseng-Williamson (2017)
10.1016/j.eururo.2017.11.021
The Current State of Predicting Response on Bacillus Calmette-Guérin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action.
Jorg R Oddens (2018)
10.1016/J.FPUROL.2016.10.002
Instillation postopératoire précoce de chimiothérapie après néphro-urétérectomie totale pour tumeur de la voie excrétrice urinaire supérieure
Pierre Colin (2016)
10.1080/17425255.2017.1341490
Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer
R. Phillips (2017)
10.1007/978-3-319-72194-1_2
Clinical Pathology of the Urinary Bladder
George Agrogiannis (2018)
10.1016/j.eururo.2016.11.029
Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61.
M. Babjuk (2017)
10.33719/yud.595945
Antiplatelet İlaç Kullanımının Mesane Kanseri Tanısı Üzerindeki Etkileri: Kolaylaştırıcı mı, Zorlaştırıcı mı?
Haci Ibrahim Cimen (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar